WHO To Assess Quality Of Biosimilar Products To Fill Regulatory Gap

Reuters: Gap in regulating biotech drug copies prompts WHO to step in
“Cut-price copies of expensive biotech drugs promise to slash the cost of treating serious diseases, including cancer, in rich and poor countries alike — but uneven regulation has created a lopsided market. Now the World Health Organization (WHO) is stepping in to assess the quality of such so-called biosimilars, offering a global stamp of approval that could make them more widely available, while also raising the quality bar…” (Hirschler/Siddiqui, 5/30).